Alle Fälle anzeigen
UPC APP 27016/2025
—·EP2279254 +1 more: NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY
- Verfahrensdetails
- Status—VerfahrensartVerfahrensantragKategorieVerfahrensführungsanordnungen
- Parteien
- Beklagte
- Moderna, Inc.
- ModernaTX, Inc.
- Moderna Belgium S.R.L.
- Moderna Italy S.R.L.
- Moderna France SASU
- Moderna Biotech UK Limited
- Moderna Switzerland GmbH
- Moderna Poland SP. Z.O.O.
- Moderna Portugal Unipessoal LDA
- Moderna Sweden AB
- Moderna Netherlands B.V.
- Moderna Biotech Spain SL
- Moderna Denmark ApS
- Moderna Germany GmbH
- Moderna Norway AS
Vertreter: Ruben Laddé; Joachim Renken - Division
- The Hague LD
- Richter
- —
- Technology
- Biotechnology
- Sprache
- —
- Erste Entscheidung
- 12. Juni 2025
Entscheidungen
- 2025-06-12Application Rop 333
The Hague Local Division issued a procedural order on a R. 333 RoP application by various Moderna entities (defendants) regarding service and deadlines for filing the Statement of Defence in infringement proceedings brought by Arbutus Biopharma and Genevant Sciences. The court denied requests to stay service or extend deadlines for individual defendants not yet formally served, while setting a single consolidated deadline for all Moderna group defendants to file one joint Statement of Defence.
Rechtsfragen:Service of process on multiple defendants (R. 333 RoP)Streamlining deadlines for corporate group defendantsConsolidated Statement of Defence by group defendantsExpeditious proceedings in pharmaceutical patent infringement
Dokumente
- 67F1D71B9121801523F195BB2BA1D2DE_en.pdf2025-06-12EN